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Circulating Interleukin-6 Receptor in Patients with Sepsis Syndrome
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John Wijdenes, Jos W. M . van der Meer, University Hospital Nijmegen, Nijmegen, Netherlands; Innotherapie
Claude Clement, Cees J. van der Linden, Laboratoires, Besançon, France
and Robert W. Sauerwein
C oncentrations of interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), and soluble tum or necro­
sis factor receptor (sTN FR ) p55 and p75 were measured in 25 patients with sepsis syndrome.
Sequential blood samples were drawn from patients during a 7-h period. IL-6 concentrations 
were 34 -76 3 ,0 0 0  pg /m L ; they were higher in nonsurvivors than  survivors, but the difference was 
not statistically significant. In septic patients, the median sIL-6R concentration was significantly 
lower than in 19 healthy volunteers (43 vs. 80 ng /m L ). SÏL-6R concentrations in survivors were 
not significantly different than those in nonsurvivors. There was a negative correlation between 
IL-6 and sIL-6R in septic patients (r = —.72). In patients with moderately impaired renal func­
tion, SÏL-6R levels were not affected, but the concentrations o f  sT N F R s were significantly 
higher.
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C ytok ines  play a pivotal role in the g en e ra t io n  o f  sepsis 
synd rom e. T h e  p resence  o f  high p lasm a  levels o f  cy tok ines  
such as in te r leuk in  ( I L ) - 1, tu m o r  necrosis fac tor (T N F ) ,  an d  
IL-6 is par ticu larly  associa ted  w ith  disease severity  a n d  prog­
nosis. R ecen tly ,  how ever, it has b eco m e  ev id en t th a t  n o t  
on ly  the  cy tok ine  b u t  also  c ircu la ting  cy tok ine  recep to rs  a n d  
c y to k in e -c y to k in e  recep to r  co m p lex es  are  invo lved  in the  
effects o f  cy tok ines  in sepsis.
Several cy tok ines, in c lu d in g  IL-6 [1] a n d  T N F  [2], have 
c ircu la ting  so lub le  receptors , w hich  have a m o d u la t in g  effect 
on  the ir  activity . F o r  ex am p le ,  b in d in g  o f  T N F  to its so lub le  
recep to r  inh ib its  its b iologic activity , the reby  p ro tec t in g  the 
o rgan ism  from the ha rm fu l effects o f  excessive T N F  [2]. 
H ow ever, low c o n c e n tra t io n s  o f  so lub le  T N F  recep tors  
( s T N F R s )  can  a u g m e n t  the  effects o f  the  cy tok ine  by in ­
creasing  its half-life [3]. In con tras t ,  the  so lub le  IL-6 recep to r  
(s IL -6R ) seem s to s t im u la te  the  biologic activ ity  o f  IL-6. In 
the  p resence  o f  sIL -6R , the  IL -6 -s t im u la te d  p ro d u c t io n  o f  
acu te -p h ase  p ro te in s  in hepa tic  cell cu ltu res  is e n h a n c e d  [4] 
a n d  IL - 6 -d e p e n d e n t  m y e lo m a  cell lines show  increased  
g row th  [5].
sIL -6R  is a 50- to 5 5 -k D a  l igand -b ind ing  p ro te in  th a t  
b inds  IL-6. It is the  ex trace l lu la r  part  o f  the  g p 8 0  su b u n i t  
from the m e m b ra n e -a n c h o re d  IL-6 receptor. W h e n  IL-6 is 
b o u n d  to m e m b ra n e -a n c h o re d  gp80 , the  co m p lex  associates
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with a signal t ran sd u c in g  su b u n it ,  gp 130, tha t  genera tes  a 
signal in to  the  cell [6].
In septic pa tien ts ,  levels o f  c ircu la ting  IL-6 co rre la te  well 
w ith  the  severity o f  disease a n d  p a t ie n t  m orta li ty  [7]. Since 
sIL -6R  m ay strongly  m o d u la te  the  effects o f  IL-6, we s tud ied  
the  c ircu la ting  levels o f  IL-6 a n d  s IL -6R  in a g ro u p  o f  septic  
pa tien ts . W e also  d e te rm in e d  b o th  so lub le  T N F  recep to rs  
(sT N F R s;  p55 a n d  p 7 5 )  to co m p a re  the ir  p a t te rn s  w ith  those  
o f  sIL-6R . D ifferent p a t te rn s  w ere ex p ec ted  because  o f  the 
a ssu m ed  differences in biologic func tion .
Materials and Methods
Patients. Sixteen men and 9 w om en with a mean age o f  58 
years (range, 18-86) participated in the study. They were se­
lected from patients in the intensive care unit o f  the University 
Hospital Nijmegen. All study patients had sepsis syndrome ac­
cording to the criteria o f  Bone [8]. In brief, patients had clinical 
evidence o f  infection, tachycardia, fever or hypothermia, and 
tachypnea, accom panied by at least one o f  the following m ani­
festations o f  inadequate organ function or perfusion: alteration 
o f  mental status, hypoxemia, metabolic acidosis, oliguria, or dis­
seminated intravascular coagulation. Exclusion criteria were the 
use o f  > 2 0  mg/day ofglucocorticosteroids and  a creatinine clear­
ance o f  < 1 0  m L/m in .
Nineteen o f  the 25 patients were in shock, which was defined 
as a sustained decrease o f  systolic blood pressure to < 9 0  m m  Hg 
or a drop o f  40 mm Hg from baseline or the presence o f  any 
vasopressors. A PA C H E II scores were calculated over the 24-h 
period before study inclusion (m ean ±  SD, 20.0 ±  5.6; range, 
9 -30 ) .  For calculation o f  the scores, the Glasgow com a score
(15) was estimated to be normal because most patients were 
sedated at testing.
At study entry, 6 patients had bacteremia: Blood cultures re­
vealed gram-negative rods in 3 patients, gram-positive cocci in 
1, and mixed flora in 2. T he  infectious diagnoses o f  the nonbac- 
teremic patients included peritonitis (6), pneum onia  (3), pye­
lonephritis (1), catheter-site infection (2), soft tissue infection
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(2), and mediastinitis (1). In 4 patients, no definite infectious 
diagnosis could be made. Nine patients (36%) died within 30 
days after inclusion. The estimated mortality rate for the patient 
group, according to the calculated APACHE II score, was 30%- 
40%.
Patient samples. Starting 30 min before the first dose of anti­
biotic and then 0, 1 ,2 , 4, and 6 h later, blood samples were 
drawn from each participant. Serum samples were allowed to 
clot at room temperature, and sera were collected after centrifu­
gation. Plasma was collected in 4-mL tubes (Vacutainer System; 
Becton Dickinson, Rutherford, NJ) containing 48 pL  of 15% 
EDTA(K3) and 250 of aprotinin (Bayer, Leverkusen, Ger­
many). Sera and plasma were stored at —20°C until use.
Control samples. As controls, 1 blood sample was drawn 
from each of 19 healthy hospital employees. Data on age and 
sex were not collected.
IL-6 andsIL-ôR ELISA. IL-6 and sIL-6R ELISAs were used 
as described [6]. The detection ranges of the ELISAs were 20- 
800 pg/mL (IL-6 ) and 0.4-25.0 ng/mL (sIL-6R). Neither the 
addition of IL-6 to sIL-6R nor the addition of sIL-6R to IL-6 
influenced the detection of the cytokine or its soluble receptor
[6]. IL-6 and sIL-6R were determined in serum.
sTNFR p55 and p75 determinations. sTNFRs were deter­
mined in plasma using an enzyme-linked immunobinding assay 
provided by H. Gallati (Hoffmann-La Roche, Basel, Switzer­
land). Detection levels were 80 pg/mL for p55 and 300 pg/mL 
for p75. In healthy volunteers, normal values (median ±  SD) are 
1470 ±  190 pg/mL for p55 and 2520 ±  660 pg/mL for p75 [9].
Statistical analysis. Spearman’s correlation coefficients 
were used to calculate the relationship between IL-6 and sIL-6R 
levels and APACHE II scores. Differences between groups were 
tested using the Wilcoxon rank sum test: P < .05 was considered 
significant, two-tailed test.
Results
Over the 7-h study period, which began 30 min before 
administration o f  antibiotic, the mean coefficient o f  varia­
tion for sIL-6R and IL-6 in the septic patients was 16% and 
36%, respectively; thus, there were only minor variations. 
Figure 1 shows the median values for each patient.
IL-6 concentrations were elevated in all patients (range, 
34-736 ,000  pg/mL). Although not statistically significant (P 
= .4), median IL-6 concentrations in the nonsurvivor group 
(3060 pg/mL) were higher than in the survivor group (988 
pg/mL). IL-6 concentrations in the healthy volunteers were 
all below the detection limit (< 2 0  pg/mL) and statistically 
different from the patients (P < .0001).
The median level o f  circulating sIL-6R in the control 
group was 80 ng/mL (range, 46-1 15). In septic patients, 
however, sIL-6R levels were significantly reduced (median, 
43 ne/mL; ranee, 10-165) compared with the healthy con­
trols (P = .0001).
There was a strong negative correlation between median 
levels o f  IL-6 and the accompanying sIL-6R in septic pa­
tients (r = —.72; P = .0001). The median levels o f  IL-6 for 
each patient correlate well with the APACHE II score (/• = 
.50; P = .01). For the median sIL-6R levels no significant 
correlation was found with the APACHE II score. W hen the 
IL-6:sIL-6R ratio was calculated and related to APACHE II 
scores, the Spearman correlation coefficient remained the 
same as for IL-6 alone (/* = .50, P = .01).
sTNFR p55 and p75 concentrations were also determined 
in the septic patients. The mean coefficient o f  variation for 
sTNFR p55 and p75 were 8% and 10%, respectively, indicat-
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Figure 1. Median IL-6 and solu­
ble IL-6 receptor (sIL-6R) concen­
trations of patients and healthy 
control group (C). S, survivors; NS, 
nonsurvivors. *, P > .05; P = 
.0001; *, P < .0001 (Wilcoxon 
rank sum test).
C S NS C S NS
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ing a stable concentration during the study period. sTNFR 
concentrations, determined in 23 patients, ranged from 2.4 
to 30.9 ng/mL for p55 and from 5.4 to 75.8 ng/mL for p75. 
Neither receptor level differed significantly between survi­
vors and nonsurvivors during the study. There was no signifi­
cant correlation between sTNFRs and sIL-6R.
To investigate the role o f  renal function in maintaining 
soluble receptor levels, patients were divided into groups 
with normal (n = 18) or impaired (n -  7) renal function 
(creatinine concentration range, 0 .6 -1 .9  and 2 .0 -3 .4  mg/ 
100 mL, respectively). Median concentrations o f  sIL-6R in 
patients with normal renal function (43.3 ng/mL) did not 
significantly differ from patients with impaired renal func­
tion (43.0 ng/mL). However, sTN FR levels were signifi­
cantly higher in patients with impaired renal function (p55, 
1 7.6 ng/mL; p75, 31.6 ng/mL) than in patients with normal 
renal function (p55, 6.4 ng/mL [P < .001 ]; p75, 11.7 ng/mL 
[ƒ>< .005]).
Discussion
The principal finding in this study was that patients with 
sepsis syndrome have decreased circulatory concentrations 
o f  sIL-6R with concomitantly high concentrations o f  IL-6. 
The concentrations o f  sIL-6R in normal volunteers were 
comparable to those previously described [1, 5]. Compared 
with the control group, septic patients in the current study 
had significantly lower concentrations o f  sIL-6R. These data 
contrast with the findings reported in HIV-seropositive pa­
tients and patients with monoclonal gammopathy, in whom 
levels o f  sIL-6R were elevated compared with controls [ 1, 5]. 
These diseases are obviously fundamentally different from 
sepsis, but increased IL-6 concentrations have been de­
scribed in patients with all three diseases [10, 11]. Appar­
ently, in HIV-seropositive patients and patients with m ono­
clonal gammopathy, the relationship between IL-6 and 
sIL-6R is different from the one in sepsis; however, to our 
knowledge, a study measuring both IL-6 and sIL-6R in these 
patients has not been published.
How sIL-6R concentrations are regulated is not clear. Pos­
sibly the IL-6/sIL-6R complex is internalized by the effector 
cells, resulting in a decreased expression o f  gp80 on the cell 
surface [12]. Assuming that membrane-anchored IL-6R is 
the main source o f  sIL-6R, the increased turnover o f  m em ­
brane-anchored IL-6R in the presence o f  high levels o f  IL-6 
might be responsible for the decreased levels o f  sIL-6R.
It is known that sIL-6R is generated either by shedding o f  
the membrane-anchored gp80 [13] or by direct production 
o f  an sIL-6R form through transcription o f  a specific m RN A
[14]. How this production is regulated has not been deter­
mined. Protein kinase C (PKC) seems to play an important 
role in shedding. Inhibitors o f  PKC might have a down-regu­
lating effect on sIL-6R production. IL-6 seems to have no 
effect on shedding o f  the gp80 ligand-binding protein [13].
Snyers and Content [15] showed that the expression o f  the 
gp 130 com ponent o f  IL-6R is enhanced by IL-6. The expres­
sion o f  both components, however, may be regulated by dif­
ferent mechanisms.
Preliminary results o f  ex vivo whole blood assays suggest 
that circulating cells are probably not involved in the produc­
tion or use o f  sIL-6R. W hen LPS is added to whole blood, 
IL-6 is produced in large am ounts (*$100,000 pg/mL). How­
ever, compared with concentrations in control blood sam­
ples, without the addition o f  LPS the concentration o f  sIL- 
6R does not change (unpublished data).
Other researchers have also found elevated levels o f  circu­
lating T N F  receptors in patients with severe infections (e.g., 
sepsis, malaria, and meningococcemia). In our study group, 
both T N F  and IL-6 were increased during sepsis, but the 
pattern o f  their soluble receptors is different and the concen­
trations were not correlated. These findings suggest a differ­
ent biologic role for both cytokine receptors: sTNFR may 
inhibit and sIL-6R enhances the biologic effects o f  TNFcx 
and IL-6, respectively.
It is well known that concentrations o f  sTNFRs in sepsis 
are influenced by renal function [16]. In this study, we con­
firm that septic patients with renal impairment have higher 
sTNFR concentrations. For sIL-6R, no relation with the cre­
atinine levels was found. This suggests that the renal clear­
ance o f  sIL-6R is not an important way to regulate levels. 
This idea is supported by the fact that only small amounts o f  
sIL-6R are found in the urine o f  healthy humans compared 
with circulating concentrations [6]. However, because pa­
tients with a renal clearance o f  < 1 0  mL/m in were excluded 
from this study, no definitive conclusions can be drawn. Pre­
liminary results in patients with chronic hemodialysis indi- 
cate an increase in basal levels o f  sIL-6R. This means that 
moderate renal impairment influences sTN FR concentra­
tions but not sIL-6R concentrations.
In previous in vitro studies, the biologic effects o f  sIL-6R 
[4, 5] were different from the biologic effects o f  sTN FR  [2]. 
Here we demonstrate that the in vivo pattern o f  sIL-6R in 
septic patients is also different from that o f  sTNFR. We can 
only speculate on the biologic significance o f  the reduction 
o f  sIL-6R during sepsis. It might be a way to decrease the 
biologic activity o f  IL-6 or just a result o f  internalization of  
IL-6 together with its receptor.
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Interleukin-10 and the Monocyte/Macrophage-Induced Inflammatory Response 
in Septic Shock
J. Gómez-Jiménez, M. C. Martin, R. Sauri, Critical Care Unit. Department o f Biochemistry. Vail d'Hebron General
R. M. Segura, F. Esteban, J. C. Ruiz, X. Nuvials, Hospital, Autonomous University, Barcelona, Spain
J. L. Bóveda, R. Peracaula, and A. Salgado
Interleukin (IL)-10 is a potent immunosuppressant of monocyte/macrophage function and 
may help control the inflammatory response induced by bacterial infection. To analyze whether 
IL-10 is detectable in plasma of patients with septic shock and to evaluate its relationship with 
endotoxin (lipopolysaccharide [LPS])-induced and monocyte/macrophage-induced inflamma­
tory response, plasma IL-10, tumor necrosis factor (TNF)-a, IL-lß, IL-6, IL-8, LPS, and neop- 
terin were studied in 24 patients with septic shock and in 12 critically ill patients. Eighty-three 
percent of patients with septic shock and 25% of critically ill patients had detectable levels of 
IL-10 (P < .001). There was a significant correlation between plasma IL-10, neopterin (r = .72),
TNF-a (r = .76), IL-6 (r = .68), and IL-8 (r = .61) levels in patients with septic shock. Monocyte/ 
macrophage activation leads to massive secretion of IL-10, which, however, seems to be unable to 
control the increased production of proinflammatory mediators during septic shock.
Interleukin (IL)-10 is a recently characterized cytokine [ 1, 
2], which has been implicated in the regulation o f  lymphoid 
and myeloid cell functions [3] because o f  its ability to sup-
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press the synthesis o f  proinflammatory cytokines from T 
cells [2], polymorphonuclear leukocytes [4], and monocytes/ 
macrophages [5-7]. In the latter case, IL-10 profoundly sup­
presses the induced production o f  tumor necrosis factor 
(TN F)-a , IL-lß , IL-6, and IL-8 by human monocytes [5]. 
Recent studies suggest that IL-10 production in human 
monocytes is controlled by bacterial lipopolysaccharide 
(LPS)-induced T N F -a  [8].
To analyze whether IL-10 is detectable in plasma of  pa­
tients with septic shock, we compared the levels o f  IL-10, 
neopterin, endotoxin, TN F-a, and IL-lß , -6, and -8 in septic 
shock patients with those in critically ill patients. We also 
used these levels to analyze the relationship between plasma
